Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;50(13):2182-2193.
doi: 10.1017/S0033291719002277. Epub 2019 Sep 16.

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis

Affiliations
Free PMC article

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis

Kirsten B Bojesen et al. Psychol Med. 2020 Oct.
Free PMC article

Abstract

Background: Poor response to dopaminergic antipsychotics constitutes a major challenge in the treatment of psychotic disorders and markers for non-response during first-episode are warranted. Previous studies have found increased levels of glutamate and γ-aminobutyric acid (GABA) in non-responding first-episode patients compared to responders, but it is unknown if non-responders can be identified using reference levels from healthy controls (HCs).

Methods: Thirty-nine antipsychotic-naïve patients with first-episode psychosis and 36 matched HCs underwent repeated assessments with the Positive and Negative Syndrome Scale and 3T magnetic resonance spectroscopy. Glutamate scaled to total creatine (/Cr) was measured in the anterior cingulate cortex (ACC) and left thalamus, and levels of GABA/Cr were measured in ACC. After 6 weeks, we re-examined 32 patients on aripiprazole monotherapy and 35 HCs, and after 26 weeks we re-examined 30 patients on naturalistic antipsychotic treatment and 32 HCs. The Andreasen criteria defined non-response.

Results: Before treatment, thalamic glutamate/Cr was higher in the whole group of patients but levels normalized after treatment. ACC levels of glutamate/Cr and GABA/Cr were lower at all assessments and unaffected by treatment. When compared with HCs, non-responders at week 6 (19 patients) and week 26 (16 patients) had higher baseline glutamate/Cr in the thalamus. Moreover, non-responders at 26 weeks had lower baseline GABA/Cr in ACC. Baseline levels in responders and HCs did not differ.

Conclusion: Glutamatergic and GABAergic abnormalities in antipsychotic-naïve patients appear driven by non-responders to antipsychotic treatment. If replicated, normative reference levels for glutamate and GABA may aid estimation of clinical prognosis in first-episode psychosis patients.

Keywords: Anterior cingulate cortex; GABA; antipsychotic-naïve; first-episode psychosis; glutamate; magnetic resonance spectroscopy; thalamus; treatment outcome.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The trajectory of mean glutamate/Cr levels in the left thalamus (a) and anterior cingulate cortex (ACC) (b) and GABA/Cr levels in ACC (c) of initially antipsychotic-naïve patients with first-episode psychosis (black line) and healthy controls (grey line) at baseline, and after 6 weeks monotherapy with aripiprazole, and 26 weeks of naturalistic antipsychotic treatment. The vertical bars represent standard errors. *p < 0.05 in post hoc testing. Note that the Y-axis does not origin in 0;0.
Fig. 2.
Fig. 2.
Baseline levels of glutamate/Cr in the thalamus and GABA/Cr in the anterior cingulate cortex (ACC) of responders (black plusses), non-responders (black circles), and healthy controls (grey diamonds). Mean values are represented by horizontal bars. Baseline glutamate/Cr levels in the left thalamus are shown according to treatment response after 6 weeks (A) and 26 weeks (B), and baseline GABA/Cr levels are shown according to treatment response after 26 weeks (C). *p < 0.025. Note that the Y-axis does not origin in 0;0.

Similar articles

Cited by

References

    1. Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D, Gomez Mancilla B, Sovago J, Buck A and Hasler G (2013) Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proceedings of the National Academy of Sciences of the USA 110, 737–742. - PMC - PubMed
    1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR and Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162, 441–449. - PubMed
    1. Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW, Menon RS, Rajakumar N, Pavlosky WF, Densmore M, Schaefer B and Williamson PC (2011) Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. The British Journal of Psychiatry 198, 448–456. - PubMed
    1. Bojesen KB, Andersen KA, Rasmussen SN, Baandrup L, Madsen LM, Glenthoj BY, Rostrup E and Broberg BV (2018) Glutamate levels and resting cerebral blood flow in anterior cingulate cortex are associated at rest and immediately following infusion of S-ketamine in healthy volunteers. Frontiers in Psychiatry 9, 22. - PMC - PubMed
    1. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ, Bolognani F, Lauriello J, Perrone-Bizzozero N and Galloway MP (2006) Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 31, 751–756. - PubMed

Publication types

MeSH terms